Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 2,537 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Like Clear all
Completed Phase 2 Interventional Results available

Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa

NCT00720122
View directory record Official record
Conditions
Disorder of Bone Density and Structure, Unspecified
Interventions
Recombinant human insulin like growth factor-1 (rhIGF-1)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 26 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

NCT05319756
View directory record Official record
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 24, 2026, 5:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1

NCT03245931
View directory record Official record
Conditions
Hepatitis C
Interventions
Qualitative Interview
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Translational Research Examining Acupuncture Treatment in Traumatic Brain Injury

NCT02623218
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Acupuncture, Sham Acupuncture
Device
Lead sponsor
AOMA Graduate School of Integrative Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

CIML NK Cell in Head & Neck Cancer

NCT04290546
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

NCT06465186
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
Interventions
Efinopegdutide, Placebo
Combination Product
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

NCT02431559
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Durvalumab, Pegylated Liposomal Doxorubicin, Motolimod
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • New York, New York • Hilliard, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 24, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional

Self-Administered Gaming and Exercise at Home (SAGEH)

NCT05929027
View directory record Official record
Conditions
Stroke, Hand Weakness
Interventions
NoNo, occupational therapy - self directed
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 5:04 PM EDT
Withdrawn Not applicable Interventional

A Novel Intervention for Training Auditory Attention in Adolescents With Autism Spectrum Disorder

NCT03625999
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism
Interventions
video game training exercise
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
13 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 24, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional

Feasibility, Acceptability, and Preliminary Efficacy of a Novel Personalized Mobile Intervention for Suicide - Open Trial (2)

NCT05180344
View directory record Official record
Conditions
Suicide, Suicide and Self-harm, Suicide, Attempted, Suicidal Ideation
Interventions
Mobile Application to Prevent Suicide (MAPS)
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 26 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

NCT00125164
View directory record Official record
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin, Tercica, Inc.)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years to 12 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Not applicable Interventional Results available

Evaluation of a CarePartner-Integrated Telehealth Rehabilitation Program for Persons With Stroke

NCT02703532
View directory record Official record
Conditions
Stroke
Interventions
CARE-CITE Education Program, Traditional Education, Constraint-Induced Movement Therapy (CIMT)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 24, 2026, 5:04 PM EDT
Terminated Phase 1 Interventional

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

NCT05144347
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
XL114
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Results available

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

NCT02299050
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cycloset
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 69 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

NCT03897205
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Imlifidase, Plasma Exchange
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 24, 2026, 5:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

4 mA tDCS, Estrogen, and Leg Muscle Fatigability

NCT04471805
View directory record Official record
Conditions
Healthy
Interventions
Sham transcranial direct current stimulation 4 mA, Transcranial direct current stimulation 4 mA
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 24, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

NCT01672866
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 24, 2026, 5:04 PM EDT
Not listed No phase listed Observational

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

NCT04034524
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist, Insulin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 24, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Knee Osteoarthritis Rehabilitation Through Rotational Inertia

NCT07424352
View directory record Official record
Conditions
Knee Arthritis, Osteoarthritis
Interventions
Eccentric resistance training
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 24, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional

Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification

NCT05766735
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Routine Care + Glycemic Excursion Minimization (RC+GEM), Routine Care (RC)
Behavioral · Other
Lead sponsor
Chiara Fabris, PhD
Other
Eligibility
30 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 24, 2026, 5:04 PM EDT
Active, not recruiting Not applicable Interventional

Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers

NCT05157880
View directory record Official record
Conditions
Acute Neurological Injury, Emotional Distress
Interventions
Recovering Together
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 5:04 PM EDT
Recruiting Phase 4 Interventional

Incretin Therapies in Obesity-related HFpEF

NCT07554638
View directory record Official record
Conditions
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 24, 2026, 5:04 PM EDT
Recruiting Not applicable Interventional

Teen Brain Online II: Understanding How Social Media Affects the Teen Brain

NCT06817993
View directory record Official record
Conditions
Depression
Interventions
Rejection and Acceptance Feedback
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

NCT00351221
View directory record Official record
Conditions
Noonan Syndrome
Interventions
rhIGF-1/rhIGFBP-3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
U.S. locations
2
States / cities
New Hyde Park, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2007 · Synced Oct 24, 2026, 5:04 PM EDT